EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Rational Design and Optimisation of CRISPR‐Cas9 Delivery Systems for Targeted Genomic Transformation

Kalpana Pandya iD, Likshit S Jaisinghani, Avanish Tripathi iD, Dileep Kumar, Sunny Kumar Saraf, Jagannath Sahoo, Devendra Kumar iD

The Journal of Gene Medicine · 2026-05 · 28 (5)

DOI: 10.1002/jgm.70095 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Gene Medicine, online erschienen am 10.05.2026. Verfasst von Kalpana Pandya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmacy & Technology Management, SVKM's NMIMS University, Mukesh Patel Technology Park, Mumbai, Ma…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Transfer Techniques, Gene Editing, Genetic Therapy. Die Arbeit nennt 102 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CRISPR‐Cas9 genome‐editing technique offers a promising therapeutic strategy for genetic disorders, including neurodegenerative diseases like Alzheimer's disease (AD), characterised by inherited susceptibility and progressive cognitive decline, as well as other hallmarks such as amyloid beta (Aβ 1–42 ) plaques and neurofibril tangles (NFTs). However, the blood–brain barrier (BBB) poses a significant challenge to the effectiveness of gene editing components in the affected brain region and impedes clinical translation. This comprehensive review compares various CRISPR‐Cas9 delivery vectors, viral, nonviral and physical, with a focus on their efficacy in neurological diseases such as AD. Viral vectors viz., adeno‐associated viruses (AAVs) and lentiviruses (LVs) demonstrate high transduction efficiency and BBB permeability. AAVs are preferred for their low immunogenicity, minimal toxicity, high neuronal tropism and episomal persistence, enabling sustained expression without insertional mutagenesis. LVs offer larger genetic payloads but raise concerns about genomic integration and potential oncogenesis, though integration‐defective variants mitigate these risks. Nonviral vectors, including peptide and polymer‐based nanoparticles, lipid nanoparticles (LNPs) and Inorganic carriers such as gold and silver nanoparticles, are less immunogenic and easier to handle but require further optimisation for in vivo BBB crossing and endosomal escape. Physical methods such as electroporation and microinjection are suitable for in vitro/ex vivo use, while novel CNS‐targeted strategies, such as RVG‐tagged particles, TfR‐directed LNPs and engineered AAV variants, enhance brain penetration via receptor‐mediated transcytosis. These preclinical studies show that these technologies can successfully edit genes and provide therapeutic benefits, including amyloid reduction and cognitive improvement in AD models. Yet off‐target effects, immune responses and regulatory hurdles persist. Overall, continuous innovation in delivery vector design and safety profile‐targeting strategies is crucial for advancing CRISPR‐Cas9 towards clinical therapies for AD‐based therapies and related neurological disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsGene Transfer TechniquesGene EditingGenetic TherapyTransformation, GeneticHumansGenetic VectorsAnimalsBlood-Brain BarrierDependovirus

Stichwörter der Autor:innen

CRISPR‐Cas9blood–brain barrierdelivery vectorsgene editingneurological disorders

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, School of Pharmacy & Technology Management, SVKM's NMIMS University, Mukesh Patel Technology Park, Mumbai, Maharashtra, India.
  • Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-Be-University, Mumbai, Maharashtra, India.
  • School of Pharmacy, ITM University, Gwalior, Madhya Pradesh, India.
  • Department of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Manipal, Karnataka, India.
  • Faculty of Pharmacy, DIT University, Dehradun, Uttarakhand, India.

ORCID-Profile: Kalpana Pandya, Avanish Tripathi, Devendra Kumar

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Pandya, K., Jaisinghani, L. S., Tripathi, A., Kumar, D., Saraf, S. K., Sahoo, J., & Kumar, D. (2026). Rational Design and Optimisation of CRISPR‐Cas9 Delivery Systems for Targeted Genomic Transformation. The Journal of Gene Medicine, 28(5). https://doi.org/10.1002/jgm.70095

Vancouver

Pandya K, Jaisinghani LS, Tripathi A, Kumar D, Saraf SK, Sahoo J, et al. Rational Design and Optimisation of CRISPR‐Cas9 Delivery Systems for Targeted Genomic Transformation. The Journal of Gene Medicine. 2026;28(5). doi:10.1002/jgm.70095

BibTeX
@article{Pandya2026,
  author = {Pandya, Kalpana and Jaisinghani, Likshit S and Tripathi, Avanish and Kumar, Dileep and Saraf, Sunny Kumar and Sahoo, Jagannath and Kumar, Devendra},
  title = {Rational Design and Optimisation of CRISPR‐Cas9 Delivery Systems for Targeted Genomic Transformation},
  journal = {The Journal of Gene Medicine},
  year = {2026},
  volume = {28},
  number = {5},
  doi = {10.1002/jgm.70095}
}
Kostenlos starten →